AKBA
Akebia Therapeutics, Inc.
Biotechnology
Market Cap$317M
5Y Perf.-89.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
AKBA vs ANIP vs INVA vs FOLD
Revenue, margins, valuation, and 5-year total return — side by side.
ANIP
ANI Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$1.78B
5Y Perf.+170.2%
INVA
Innoviva, Inc.
Biotechnology
Market Cap$1.93B
5Y Perf.+63.2%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+15.9%
AKBA vs ANIP vs INVA vs FOLD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AKBA | ANIP | INVA | FOLD |
|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Biotechnology | Biotechnology |
| Market Cap | $317M | $1.78B | $1.93B | $4.55B |
| Revenue (TTM) | $232M | $883M | $424M | $634M |
| Net Income (TTM) | $-21M | $78M | $504M | $-27M |
| Gross Margin | 81.0% | 69.1% | 76.2% | 87.9% |
| Operating Margin | 2.3% | 12.6% | 14.8% | 5.2% |
| Forward P/E | — | 9.2x | 11.9x | 40.6x |
| Total Debt | $216M | $325M | $269M | $483M |
| Cash & Equiv. | $185M | $286M | $551M | $214M |
AKBA vs ANIP vs INVA vs FOLD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AKBA
ANIP
INVA
FOLD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Akebia Therapeutics… (AKBA) | 100 | 10.1 | -89.9% |
| ANI Pharmaceuticals… (ANIP) | 100 | 270.2 | +170.2% |
| Innoviva, Inc. (INVA) | 100 | 163.2 | +63.2% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AKBA vs ANIP vs INVA vs FOLD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: INVA leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. ANI Pharmaceuticals, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. AKBA and FOLD also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
AKBA
Akebia Therapeutics, Inc.
The Growth Leader
AKBA is the clearest fit if your priority is growth.
- 47.5% revenue growth vs INVA's 18.5%
Best for: growth
ANIP
ANI Pharmaceuticals, Inc.
The Income Pick
ANIP is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- Dividend streak 0 yrs, beta 0.63, yield 0.1%
- Rev growth 43.8%, EPS growth 419.2%, 3Y rev CAGR 40.8%
- Lower P/E (9.2x vs 40.6x)
- 0.1% yield; the other 3 pay no meaningful dividend
Best for: income & stability and growth exposure
INVA
Innoviva, Inc.
The Defensive Pick
INVA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
- Beta 0.13, current ratio 14.64x
- 118.9% margin vs AKBA's -8.8%
- Beta 0.13 vs AKBA's 1.14, lower leverage
Best for: sleep-well-at-night and defensive
FOLD
Amicus Therapeutics, Inc.
The Long-Run Compounder
FOLD is the clearest fit if your priority is long-term compounding.
- 119.2% 10Y total return vs INVA's 94.9%
- +137.9% vs AKBA's -52.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AKBA | 47.5% revenue growth vs INVA's 18.5% |
| Value | ANIP | Lower P/E (9.2x vs 40.6x) |
| Quality / Margins | INVA | 118.9% margin vs AKBA's -8.8% |
| Stability / Safety | INVA | Beta 0.13 vs AKBA's 1.14, lower leverage |
| Dividends | ANIP | 0.1% yield; the other 3 pay no meaningful dividend |
| Momentum (1Y) | FOLD | +137.9% vs AKBA's -52.0% |
| Efficiency (ROA) | INVA | 32.4% ROA vs AKBA's -5.7%, ROIC 14.2% vs 23.2% |
AKBA vs ANIP vs INVA vs FOLD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
FY 2025
Segment breakdown not available.
AKBA vs ANIP vs INVA vs FOLD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLINVALAGGINGFOLD
Who Leads Where
INVA leads in 2 of 6 categories
ANIP leads 1 • AKBA leads 0 • FOLD leads 0 • 2 tied
Explore the data ↓FOLDAmicus Therapeutics, …
0leads
AKBAAkebia Therapeutics, …
0leads
ANIPANI Pharmaceuticals, …
1leads
INVAInnoviva, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ANIPvs AKBAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
INVA4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
INVA5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ANIP3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ANIP is the larger business by revenue, generating $883M annually — 3.8x AKBA's $232M. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to AKBA's -8.8%. On growth, ANIP holds the edge at +29.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AKBAAkebia Therapeuti… | ANIPANI Pharmaceutica… | INVAInnoviva, Inc. | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $232M | $883M | $424M | $634M |
| EBITDAEarnings before interest/tax | $6M | $203M | $86M | $40M |
| Net IncomeAfter-tax profit | -$21M | $78M | $504M | -$27M |
| Free Cash FlowCash after capex | $60M | $128M | $181M | $30M |
| Gross MarginGross profit ÷ Revenue | +81.0% | +69.1% | +76.2% | +87.9% |
| Operating MarginEBIT ÷ Revenue | +2.3% | +12.6% | +14.8% | +5.2% |
| Net MarginNet income ÷ Revenue | -8.8% | +8.9% | +118.9% | -4.3% |
| FCF MarginFCF ÷ Revenue | +25.8% | +14.5% | +42.8% | +4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -6.6% | +29.6% | +10.6% | +23.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +3.1% | +4.0% | -89.0% |
INVA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — AKBA and INVA each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 6.9x trailing earnings, INVA trades at a 73% valuation discount to ANIP's 25.3x P/E. On an enterprise value basis, INVA's 8.1x EV/EBITDA is more attractive than FOLD's 114.9x.
| Metric | AKBAAkebia Therapeuti… | ANIPANI Pharmaceutica… | INVAInnoviva, Inc. | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Market CapShares × price | $317M | $1.8B | $1.9B | $4.5B |
| Enterprise ValueMkt cap + debt − cash | $348M | $1.8B | $1.7B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -56.73x | 25.27x | 6.91x | -164.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.25x | 11.91x | 40.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.67x | — |
| EV / EBITDAEnterprise value multiple | 14.05x | 8.99x | 8.10x | 114.88x |
| Price / SalesMarket cap ÷ Revenue | 1.34x | 2.02x | 4.55x | 7.17x |
| Price / BookPrice ÷ Book value/share | 9.31x | 3.29x | 1.65x | 16.29x |
| Price / FCFMarket cap ÷ FCF | 4.66x | 9.62x | 9.88x | 152.43x |
Evenly matched — AKBA and INVA each lead in 2 of 6 comparable metrics.
Profitability & Efficiency
INVA leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-63 for AKBA. INVA carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to AKBA's 6.63x. On the Piotroski fundamental quality scale (0–9), ANIP scores 6/9 vs FOLD's 4/9, reflecting solid financial health.
| Metric | AKBAAkebia Therapeuti… | ANIPANI Pharmaceutica… | INVAInnoviva, Inc. | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -62.7% | +14.5% | +46.5% | -12.0% |
| ROA (TTM)Return on assets | -5.7% | +5.4% | +32.4% | -3.2% |
| ROICReturn on invested capital | +23.2% | +11.2% | +14.2% | +5.3% |
| ROCEReturn on capital employed | +13.3% | +9.9% | +12.4% | +5.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 4 |
| Debt / EquityFinancial leverage | 6.63x | 0.60x | 0.23x | 1.76x |
| Net DebtTotal debt minus cash | $31M | $40M | -$282M | $269M |
| Cash & Equiv.Liquid assets | $185M | $286M | $551M | $214M |
| Total DebtShort + long-term debt | $216M | $325M | $269M | $483M |
| Interest CoverageEBIT ÷ Interest expense | 0.56x | 1.82x | 63.45x | 1.00x |
INVA leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ANIP leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANIP five years ago would be worth $21,738 today (with dividends reinvested), compared to $3,782 for AKBA. Over the past 12 months, FOLD leads with a +137.9% total return vs AKBA's -52.0%. The 3-year compound annual growth rate (CAGR) favors ANIP at 25.4% vs AKBA's 3.6% — a key indicator of consistent wealth creation.
| Metric | AKBAAkebia Therapeuti… | ANIPANI Pharmaceutica… | INVAInnoviva, Inc. | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -23.9% | +7.0% | +14.7% | +1.5% |
| 1-Year ReturnPast 12 months | -52.0% | +18.5% | +21.7% | +137.9% |
| 3-Year ReturnCumulative with dividends | +11.3% | +97.1% | +95.2% | +19.0% |
| 5-Year ReturnCumulative with dividends | -62.2% | +117.4% | +94.4% | +48.6% |
| 10-Year ReturnCumulative with dividends | -85.7% | +84.7% | +94.9% | +119.2% |
| CAGR (3Y)Annualised 3-year return | +3.6% | +25.4% | +25.0% | +6.0% |
ANIP leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — INVA and FOLD each lead in 1 of 2 comparable metrics.
Risk & Volatility
INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than AKBA's 1.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs AKBA's 28.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AKBAAkebia Therapeuti… | ANIPANI Pharmaceutica… | INVAInnoviva, Inc. | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 0.63x | 0.13x | 0.63x |
| 52-Week HighHighest price in past year | $4.08 | $99.50 | $25.15 | $14.50 |
| 52-Week LowLowest price in past year | $1.13 | $56.71 | $16.52 | $5.51 |
| % of 52W HighCurrent price vs 52-week peak | +28.9% | +84.3% | +90.7% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 55.9 | 64.4 | 39.9 | 72.2 |
| Avg Volume (50D)Average daily shares traded | 2.8M | 328K | 621K | 3.0M |
Evenly matched — INVA and FOLD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AKBA as "Buy", ANIP as "Buy", INVA as "Buy", FOLD as "Buy". Consensus price targets imply 239.0% upside for AKBA (target: $4) vs 0.1% for FOLD (target: $15).
| Metric | AKBAAkebia Therapeuti… | ANIPANI Pharmaceutica… | INVAInnoviva, Inc. | FOLDAmicus Therapeuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $124.00 | $37.67 | $14.50 |
| # AnalystsCovering analysts | 11 | 10 | 10 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | +0.1% | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | $0.05 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.7% | +0.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
INVA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ANIP leads in 1 (Total Returns). 2 tied.
Best OverallInnoviva, Inc. (INVA)Leads 2 of 6 categories
Loading custom metrics...
AKBA vs ANIP vs INVA vs FOLD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AKBA or ANIP or INVA or FOLD a better buy right now?
For growth investors, Akebia Therapeutics, Inc.
(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus 18. 5% for Innoviva, Inc. (INVA). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Akebia Therapeutics, Inc. (AKBA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AKBA or ANIP or INVA or FOLD?
On trailing P/E, Innoviva, Inc.
(INVA) is the cheapest at 6. 9x versus ANI Pharmaceuticals, Inc. at 25. 3x. On forward P/E, ANI Pharmaceuticals, Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — AKBA or ANIP or INVA or FOLD?
Over the past 5 years, ANI Pharmaceuticals, Inc.
(ANIP) delivered a total return of +117. 4%, compared to -62. 2% for Akebia Therapeutics, Inc. (AKBA). Over 10 years, the gap is even starker: FOLD returned +119. 2% versus AKBA's -85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AKBA or ANIP or INVA or FOLD?
By beta (market sensitivity over 5 years), Innoviva, Inc.
(INVA) is the lower-risk stock at 0. 13β versus Akebia Therapeutics, Inc. 's 1. 14β — meaning AKBA is approximately 803% more volatile than INVA relative to the S&P 500. On balance sheet safety, Innoviva, Inc. (INVA) carries a lower debt/equity ratio of 23% versus 7% for Akebia Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AKBA or ANIP or INVA or FOLD?
By revenue growth (latest reported year), Akebia Therapeutics, Inc.
(AKBA) is pulling ahead at 47. 5% versus 18. 5% for Innoviva, Inc. (INVA). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to 51. 2% for Amicus Therapeutics, Inc.. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AKBA or ANIP or INVA or FOLD?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus -4. 3% for Amicus Therapeutics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 5. 4% for FOLD. At the gross margin level — before operating expenses — FOLD leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AKBA or ANIP or INVA or FOLD more undervalued right now?
On forward earnings alone, ANI Pharmaceuticals, Inc.
(ANIP) trades at 9. 2x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 31. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKBA: 239. 0% to $4. 00.
08Which pays a better dividend — AKBA or ANIP or INVA or FOLD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is AKBA or ANIP or INVA or FOLD better for a retirement portfolio?
For long-horizon retirement investors, Innoviva, Inc.
(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Both have compounded well over 10 years (INVA: +94. 9%, AKBA: -85. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AKBA and ANIP and INVA and FOLD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(AKBA: -6.6% · ANIP: 29.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.